Abstract The Asia–Pacific Working Group on Inflammatory Bowel Disease was established
in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology …

Background There is an increasing body of evidence showing that earlier use of biologics
improves clinical outcomes in Crohn's disease (CD). Aim To perform a systematic review …

Crohn's disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in
progressive bowel damage and disability. 1 CD can affect individuals of any age, from …

Outcomes for patients starting a new treatment for inflammatory bowel disease are
characterized by uncertainty of treatment response. Although it is natural to hope that new …

Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

Short-and long-term treatment targets in inflammatory bowel diseases (IBDs) evolved during
the last decade, shifting from symptom control to endoscopic healing and patient-centered …

Abstract Background and Aims Inflammatory bowel disease (IBD) can lead to long-term
complications that significantly impact patients' quality of life and healthcare resource …

Abstract Background and Aims The optimal timing of treatment escalation in Crohn's disease
[CD] remains a challenging issue, and very little is known about its long-term development …

Inflammatory bowel disease (IBD) is a chronic and progressive inf lammatory condition of
the gastrointestinal tract causing bowel damage, hospitalizations, surgeries, and disability …

Background Anti‐tumour necrosis factor‐α (anti‐TNF) therapy use has risen in paediatric‐
onset inflammatory bowel disease (PIBD). Whether this has translated into …